AMEX · Biotechnology

Oragenics Inc. (OGEN) Stock

$0.46 +0.41% AMEX: OGEN Healthcare

Valuation

MetricValue
Price$0.46
Market Cap$2.10M
P/E Ratio-0.14
P/B Ratio0.60
P/S Ratio0.00
EPS (TTM)$-4.56
52-Week High$1.45
52-Week Low$0.46
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-144.23%
ROA-183.59%
ROCE-285.25%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-16.0M$-14.0M$-21.0M$-11.0M$-9.0M
Net Profit$-16.0M$-14.0M$-21.0M$-11.0M$-10.0M
EPS$-8.09$-7.11$-9.18$-1.60$-4.56
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$28.0M$15.0M$5.0M$1.0M$10.0M
Total Liabilities$2.0M$2.0M$2.0M$2.0M$2.0M
Cash$27.0M$11.0M$3.0M$1.0M$4.0M
Borrowings$1.0M$1.0M$0$0$0

Latest News

Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients MT Newswires · Jul 7, 2026 Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling GlobeNewswire · Jul 7, 2026 Sidoti Events, LLC's May Micro-Cap Virtual Conference ACCESS Newswire · May 20, 2026 Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 GlobeNewswire · May 19, 2026 ORAGENICS PROVIDES INVESTOR UPDATE GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-15.0M$-7.0M$-9.0M$-9.2B
Investing Cash Flow$0$0$-2.0M$0$0
Financing Cash Flow$-5.0M$0$0$0$16.8B
Net Cash Flow$10.0M$-16.0M$-8.0M$-3.0M$7.5B
Free Cash Flow$-14.0M$-15.0M$-8.0M$-9.0M$-9.2B

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.22
FCF Yield-452.55%
Quick Ratio3.01
Interest Coverage-561.90
Return 1Y-58.21%
Return 3Y-99.50%
Return 5Y-99.95%

Ownership

Insiders Held1.93%
Institutions Held5.76%
Institutions Float Held5.88%
Institutional HolderSharesReport Date
Geode Capital Management, LLC65,0722026-03-31
Pathstone Holdings, LLC55,0012026-03-31
Two Sigma Securities, LLC20,3432026-03-31
HRT Financial LP18,6722026-03-31
Virtu Financial LLC17,5752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AIMAIM ImmunoTech Inc. $0.18 +1.00% -0.05 $7.11M 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
CNSPCNS Pharmaceuticals, Inc. $5.23 -2.24% -0.23 $7.64M 0.00%
ENSCEnsysce Biosciences, Inc. $0.52 +13.56% -0.16 $7.99M 0.00%
KALAKALA BIO, Inc. $0.29 -3.57% -0.01 $5.53M 0.00%

About Oragenics Inc.

Oragenics Inc. is led by CEO Janet Huffman, employs 3 people, headquartered in US, publicly traded since 2004.

Oragenics Inc. (OGEN) stock trades at $0.46 with a market capitalization of $2.10M. The stock is valued at a price-to-earnings (P/E) ratio of -0.14, price-to-book of 0.60, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.46 and $1.45, and currently trades 68.3% below its 52-week high.

On profitability, Oragenics Inc. generates a return on equity (ROE) of -144.23%, return on capital employed of -285.25%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1176.50 +0.59% JNJ Johnson & Johnson $260.45 +1.55% ABBV AbbVie Inc. $276.42 +1.47% MRK Merck & Company, Inc. Common Stock (new) $146.15 +2.64% UNH UnitedHealth Group Incorporated Common Stock (DE) $380.92 +2.69% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $660.31 +1.28% AMGN Amgen Inc. $417.07 +2.36% GILD Gilead Sciences, Inc. $150.86 +2.56% ABT Abbott Laboratories $99.23 +0.75% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides